Ovarian cancer detection via AI-based models
A recent study conducted in China aimed to enhance the diagnosis of ovarian cancer, a challenging task due to the lack of effective biomarkers. The st…
A recent study conducted in China aimed to enhance the diagnosis of ovarian cancer, a challenging task due to the lack of effective biomarkers. The st…
Manifest MedEx (MX), California’s largest nonprofit Qualified Health Information Organization (QHIO), is launching the California ADT Network — a no-cost, electronic ADT notification exchange — to help organizations exchange ADT data in compliance with the DxF and to substantially scale the sharing of ADT alerts across the state.
CLAYMONT, Del.--(BUSINESS WIRE)--#AI--Vital, a leading artificial intelligence- (AI) driven digital health company, announced a significant milestone with the publication of a groundbreaking peer-reviewed scientific publication in the Journal of Medica...
The FDA's Center for Devices and Radiological Health (CDRH) has announced the elevation of the Office of Strategic Partnerships and Technology Innovat…
Orion Corporation (“Orion”) and Newel Health (“Newel”) have entered into a license agreement regarding ODD-403 (“Rohkea”), a digital therapeutic (DTx)…
-Deliberate AI, a digital health technology company that delivers precision measurement of mental health through AI, today announced its inclusion in the U.S. Food and Drug Administration (FDA) Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program.
ATHERTON, Calif.--(BUSINESS WIRE)--WellTheory, a first-of-its-kind virtual solution for the 50 million Americans suffering with autoimmune disease, to…
Element Science, an innovative health technology company pioneering a digital wearable platform for high-risk cardiovascular patients, announced that it has received the European Union’s CE mark certification and Great Britain’s UK Conformity Assessed (UKCA) marking for its novel Patch Wearable Cardioverter Defibrillator (P-WCD) from its Notified Body, the BSI Group.
wift Medical, a digital health technology company serving wound care providers, is pleased to announce the successful closing of an $US8M round of financing co-led by current investors BDC Capital’s Women in Technology Venture Fund and funds managed by Virgo Investment Group.
Genialis, the RNA-biomarker company, and Debiopharm, a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, have reached an agreement to define and discover biomarkers within the DNA Damage Repair (DDR) biology space to predict the clinical benefit of one or more drugs in Debiopharm’s pipeline.